Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Deferred Taxes (2016 - 2023)

Amicus Therapeutics (FOLD) has disclosed Deferred Taxes for 3 consecutive years, with -$4.9 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Deferred Taxes changed N/A year-over-year to -$4.9 million, compared with a TTM value of -$4.9 million through Dec 2023, down 54977.78%, and an annual FY2023 reading of -$4.9 million, down 54977.78% over the prior year.
  • Deferred Taxes was -$4.9 million for Q1 2023 at Amicus Therapeutics, down from $9000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $9000.0 in Q4 2022 and bottomed at -$4.9 million in Q1 2023.